Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 27, 2018 - Issue 10
Submit an article Journal homepage
637
Views
1
CrossRef citations to date
0
Altmetric
Review

The  early  preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound

Robin KollerCenter of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands;Centre de Recherches Médicales en Lambaréné (CERMEL), Lambaréné, GabonView further author information
,
Ghyslain Mombo-NgomaCentre de Recherches Médicales en Lambaréné (CERMEL), Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine University Medical Center Hamburg-Eppendorf, Hamburg, Germany;Department of Parasitology, Université des Sciences de la Santé, Libreville, GabonView further author information
&
Martin P. GrobuschCenter of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands;Centre de Recherches Médicales en Lambaréné (CERMEL), Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa;Masanga Medical Research Unit, Masanga, Sierra LeoneCorrespondence[email protected]
View further author information
Pages 803-810 | Received 16 Jul 2018, Accepted 13 Sep 2018, Published online: 25 Sep 2018

References

  • Nagle A, Wu T, Kuhen K, et al. Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J Med Chem. 2012;55(9):4244–4273.
  • Diagana TT. Supporting malaria elimination with 21st century antimalarial agent drug discovery. Drug Discov Today. 2015;20(10):1265–1270.
  • Held J, Jeyaraj S, Kreidenweiss A, et al. Antimalarial compounds in phase II clinical development. Expert Opion Investigational Drugs. 2015;24(3):363–382.
  • Mischlinger J, Agnandji ST, Ramharter A. Single dose treatment of malaria - current status and perspectives. Expert Rev Anti Infect Ther. 2016;14(7):669–678.
  • Bhagavathula AS, Elnour AA, Shehab A. Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infect Dis Poverty. 2016;5(103).
  • World Malaria Report 2017. Geneva: World Health Organization; 2017. License: CC BY-NC-SA 3.0 IGO
  • WHO 2015. WHO guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
  • Ménard D, Khim N, Beghain J, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453–2464.
  • Ouji M, Augereau JM, Paloque L, et al. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.
  • Thu AM, Phyo AP, Landier J, et al. Combating multidrug-resistant Plasmodium falciparum malaria. FEBS J. 2017;284:2569–2578.
  • Kuhen K, Chatterjee A, Rottmann M, et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother. 2014;58(9):5060–5067.
  • Burrows JN, Duparc S, Gutteridge WE, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16:1.
  • Magistrado P, Corey V, Lukens A, et al. Plasmodium falciparum cyclic amine resistance locus (PfCARL), a resistance mechanism for two distinct compound classes. ACS Infect Dis. 2016;2(11):816–826.
  • Dembele L, Gupta DK, Lim MYX, et al. Imidazolopiperazines kill both rings and dormant rings in wild-type and K13 artemisin-resistant Plasmodium falciparum in vitro. Antimicr Agents Chemother. 2018;62:e02235–17.
  • Huskey S, Forseth R, Li H, et al. Utilization of stable isotope labeling to facilitate the identification of polar metabolites of KAF156, an antimalarial agent. Drug Metabolism and Disposition. 2016;44(10):1697–1708.
  • Leong F, Zhao R, Zeng S, et al. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014;58(11):6437–6443.
  • Leong F, Jain J, Feng Y, et al. A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine. Malar J. 2018;17:1.
  • White N, Duong T, Uthaisin C, et al. Antimalarial activity of KAF156 in falciparum and vivax malaria. New England J Med. 2016;375(12):1152–1160.
  • Nsanzabana C, Djalle D, Guérin PJ, et al. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17:1.
  • Ross LS, Dhingra SK, Mok S, et al. Emerging Southeast Asian pfcrt mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018;17:3314.
  • EMA. Summary of Eurartesim® product characteristics. [cited 2018 Jul 5]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdf
  • Jain J, Leong F, Chen L, et al. Bioavailability of lumefantrine is significantly enhanced with a novel formulation approach, an outcome from a randomized, open-label pharmacokinetic study in healthy volunteers. Antimicrob Agents Chemother. 2017;61:9.
  • Clinicaltrials.gov. Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria; [ Updated 2018 May 8; cited 2018 Apr 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03167242
  • Lim M, LaMonte G, Lee M, et al. UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nat Microbiol. 2016;1. doi:10.1038/nmicrobiol.2016.166 [Epub ahead of print]
  • [cited 2018 Sept 8]. Available from: https://www.mmv.org/research-development/project-portfolio/kaf156-lumefantrine

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.